



**HAL**  
open science

## Phosphatidylserine-expressing cell by-products in transfusion: A pro-inflammatory or an anti-inflammatory effect?

Philippe Saas, Fanny Angelot, Laurent Bardiaux, Estelle Seilles, Francine Garnache-Ottou, Sylvain Perruche

### ► To cite this version:

Philippe Saas, Fanny Angelot, Laurent Bardiaux, Estelle Seilles, Francine Garnache-Ottou, et al.. Phosphatidylserine-expressing cell by-products in transfusion: A pro-inflammatory or an anti-inflammatory effect?. *Transfusion Clinique et Biologique*, 2012, 19 (3), pp.90-7. 10.1016/j.tracli.2012.02.002 . inserm-00799527

**HAL Id: inserm-00799527**

**<https://inserm.hal.science/inserm-00799527>**

Submitted on 7 May 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Phosphatidylserine-expressing cell by-products in transfusion: a pro-inflammatory or an anti-inflammatory effect?**

**Rôle des débris cellulaires exprimant la phosphatidylserine en transfusion : un effet pro- ou anti-inflammatoire ?**

P SAAS<sup>1,2,3</sup>, F ANGELOT<sup>1,2,3</sup>, L BARDIAUX<sup>1,2,3</sup>, E SEILLES<sup>1,2,3</sup>, F GARNACHE-OTTOU<sup>1,2,3</sup>, S PERRUCHE<sup>1,2,3</sup>

<sup>1</sup>INSERM, UMR1098, BP 1937, F-25020 Besançon cedex, France.

<sup>2</sup>Université de Franche-Comté, F-25020 Besançon cedex, France.

<sup>3</sup>EFS Bourgogne Franche-Comté, 1 Bd A Fleming, F-25020 Besançon cedex, France.

Auteur correspondant/Corresponding author:

Téléphone/Phone: +33 3 81 61 56 15 ; FAX : +33 3 81 61 56 17 ; e-mail : philippe.saas@efs.sante.fr (P Saas)

**Summary:**

Labile blood products contain phosphatidylserine (PtdSer)-expressing cell dusts, including apoptotic cells and microparticles. These cell byproducts are produced during blood product process or storage and derived from the cells of interest that exert a therapeutic effect (red blood cells or platelets). Alternatively, PtdSer-expressing cell dusts may also derived from contaminating cells, such as leukocytes, or may be already present in plasma, such as platelet-derived microparticles. These cell byproducts present in labile blood products can be responsible for transfusion-induced immunomodulation leading to either TRALI or increased occurrence of post-transfusion infections or cancer relapse. In this review, we report data from the literature and our laboratory dealing with interactions between antigen-presenting cells and PtdSer-expressing cell dusts, including apoptotic leukocytes and blood cell-derived microparticles. Then, we discuss how these PtdSer-expressing cell byproducts may influence transfusion.

Key words: Apoptotic cells; Microparticles; Macrophages; Dendritic cells; TRALI; Tolerance; Inflammation; Transfusion; Treg; labile blood products

**Résumé :**

Les produits sanguins labiles contiennent des débris cellulaires qui expriment à leur surface la phosphatidylsérine, un phospholipide exprimé à la face interne de la membrane plasmique des cellules viables. Ces débris, générés durant la conservation ou la filtration des produits sanguins labiles, correspondent à des cellules en apoptose ou des microparticules. Ces débris peuvent donc influencer la transfusion et conduire à une activation du système immunitaire du patient transfusé, à l'origine du TRALI par exemple. Au contraire, ces débris cellulaires peuvent concourir à une inhibition du système immunitaire après transfusion et conduire à la survenue d'infections ou encore favoriser les récurrences de cancer. Dans cette revue, nous rapportons les données de la littérature et de notre laboratoire concernant les interactions entre les débris exprimant la phosphatidylsérine (cellules apoptotiques et microparticules) et les cellules présentatrices d'antigènes et nous discutons des éléments permettant d'expliquer le rôle pro- ou anti-inflammatoire de ces débris cellulaires lors de la transfusion.

Mots clés : Cellules apoptotiques ; Microparticules ; Macrophages ; Cellules dendritiques ; TRALI ; Tolérance ; Inflammation ; Transfusion ; Lymphocytes T régulateurs ; produits sanguins labiles

## 1. Introduction

Labile blood products contain the cells of interest (that are red blood cells [RBC], platelets) or plasma that exert their therapeutic effects, but also cell byproducts or cell dusts. These cell byproducts may play a critical role in transfusion. Here, we will discuss the influence of phosphatidylserine (PtdSer)-expressing cell dusts on immune responses and their consequences in transfusion setting. These cell byproducts may activate innate immune cells (such as antigen-presenting cells [APC]) and deliver a pro-inflammatory response observed, for instance, in antibody-independent transfusion-related acute lung injury (TRALI). Today, TRALI is on the scrutiny of the transfusion community. Indeed, TRALI is the leading cause of transfusion-related morbidity and mortality. Recent publications have reported the frequency of TRALI according to the number of transfused blood products in different countries [1, 2]. However, the risk of TRALI is not equal for all blood products. Single donor plasma transfusion carries the highest risk of TRALI (mainly immune-mediated TRALI) [3], while RBC transfusion exhibits the lowest risk of all blood products for antibody-associated TRALI [4]. Among the blood products implicated in TRALI, half are fresh-frozen plasma (FFP)[2]. Moreover, the risk is higher in intensive care units where 40% of critically ill patients receive at least one unit of RBC with a mean of 5 units per patient [5]. A “two hit” model is used to explain the occurrence of TRALI[2, 4, 5]. The first hit is related to the transfused patients and several recipient-related risk factors have been identified[2, 4, 5]. The analysis of experimental models of TRALI suggests that factors may protect or attenuate TRALI, such as T cells[4]. The second hit is linked to the transfused blood product[2, 4, 5]. Transfusion-related risk factors have been identified or suspected for plasma, RBC and platelets[4]. Some of these risks have been taken into account in transfusion practice and have significantly reduced TRALI occurrence, such as the prevention of anti-HLA antibody infusion by using male donor plasma[2, 3, 6]. Depending on factors present in blood products and triggering TRALI, TRALI can be divided up into immune (antibody-mediated) TRALI and non immune (antibody-independent) TRALI[2, 4, 5]. It has been suggested that substances released during blood product storage may cause non immune TRALI, such as free hemoglobin, iron, nitric oxide or microparticles[5]. On the

opposite to immune system activation, PtdSer-expressing cell byproducts present in blood products may inhibit innate immune cells and deliver an anti-inflammatory signal or may induce donor-specific tolerance. Such mechanisms can be involved in the immunosuppressive or tolerogenic effects of blood transfusion observed in patients. This may lead to an increased occurrence of post-transfusion infections [7] or cancer relapse [7, 8]. In addition, this may explain the effect of donor-specific transfusion (DST) in kidney transplanted patients [9-11]. Thereafter, we will discuss how PtdSer-expressing cell byproducts may participate in both sides of transfusion-related immunomodulation [8]: immune activation or inhibition (Figure 1). Before that, we will review publications reporting the presence of PtdSer-expressing cell byproducts with a special emphasis in the processes that influence their generation.

## **2. Phosphatidylserine-expressing cell byproducts in labile blood products**

Several publications report the presence of PtdSer-expressing cell byproducts in blood products [12-34] (Table 1). These cell byproducts may be generated during the blood product process, such as filtration [19] or during storage (either cold storage for RBC [12-15, 19, 24-26, 28, 34, 35] or between 20-24°C for platelets [16, 17, 20-22, 27, 29]). Alternatively, they may be limited by filtration [23, 31, 33, 36]. Phosphatidylserine-expressing cell byproducts can be apoptotic cells [13-17, 19-22, 27, 29, 34]. Apoptotic cells have been found in different blood products: RBC units [13-15, 19, 34], platelet concentrates [16, 17, 20-22, 27, 29]. These apoptotic cells correspond to dying cells of interest: RBC or platelets [16, 20-22, 27, 29], both enucleated cells that can undergo apoptosis [37]. Residual cells contaminating the blood products – such as leucocytes [13-15, 19, 34], including: lymphocytes [14], neutrophils [14, 34] or monocytes [34] – may also become apoptotic. Leukoreduction by filtration reduces the absolute number of contaminating leukocytes in blood products and thus may limit the number of apoptotic leukocytes [38, 39]. However, filtration seems also to affect leukocyte viability favoring apoptotic leukocyte production [19]. Otherwise, PtdSer-expressing cell byproducts can also be microparticles [12, 23-26, 28, 30-33, 35, 36], also known as ectosomes [40]. This corresponds to

particles with a diameter of less than one micrometer produced from plasma membrane by a mechanism called vesiculation[40]. These microparticles are generated during apoptotic process or after cell activation [26]and may originate from the cells of interest that are transfused(i.e., RBC[12, 24-26, 28]or platelets[32])and be produced during storage [12, 18, 24-26, 28, 29, 35],or alternatively, they can already be present in the plasma as microparticles can be detected in FFP[23, 33, 36].These latter correspond to circulating microparticles. The major circulating microparticles found in healthy donors are platelet-derived microparticles (PMP)followed by red blood cell-derived microparticles (RMP)[41]. Overall, the different steps of blood product process,and especially storage at 20-24°C for platelet concentrates or at 1-6°C for RBC units, generate PtdSer-expressing cell byproducts that may have consequences in transfused patients.

### **3. Immune functions of phosphatidylserine-expressing cell byproducts and potential consequences in transfusion**

#### **3.1. Immune functions of apoptotic blood cells and potential consequences in transfusion**

The anti-inflammatory properties of early stage apoptotic leukocytes are well documented in the literature (for review [42-45])(Figure 2). An early event occurring after apoptosis is the expression of “eat-me signals”, such as the expression of PtdSer at the external leaflet of plasma membrane[45-47]. Phosphatidylserine expression by apoptotic cells favors their uptake by professional phagocytes, such as macrophages or conventional dendritic cells (cDC)(for review [42, 45]). Uptake of apoptotic cells induces the secretion of anti-inflammatory cytokines, such as IL-10 or TGF- $\beta$ , as well as the inhibition of inflammatory cytokine secretion such as IL-12 or IL-1 $\beta$ , IL-6 and TNF (for review [42, 43]). Moreover, APC become resistant to Toll-like receptor (TLR) ligand activation[48, 49]. These APC do not express high levels of costimulatory molecules and if they interact with naive T cells they favor T cell anergy (for review [42]).By the release of TGF- $\beta$  after apoptotic cell internalization,APC induce the generation of regulatory T cells (Treg)[50, 51]. In this setting, generation of Treg leads to tolerance against apoptotic cell-derived antigens.

In line with these data, we have reported that intravenous apoptotic leukocyte infusion favors bone marrow engraftment when apoptotic leukocytes were infused simultaneously with an allogeneic bone marrow allograft in irradiated mice[52]. This effect is observed whatever the origin of apoptotic cells: donor, recipient and third party[52]and is dependent on TGF- $\beta$ [50, 53, 54]. Apoptotic cell-induced engraftment implicates recipient macrophages, since prior depletion of host macrophages by clodronate liposome infusion inhibits the graft facilitating effect of apoptotic cells[50].This confirms previous results on the critical role of macrophages to limit immune responses against dying cells [55, 56]. We also showed that plasmacytoid dendritic cells (PDC) are mandatory in the apoptotic cell-induced Treg both in transplantation settings, as well as in naive mice [53]. However, whereas PDC are influenced by factors (including TGF- $\beta$ ) released by macrophages uptaking apoptotic cells,PDC are not directly influenced by apoptotic cells [53].

Implication of PtdSer in the inhibition of both inflammation and specific immune responses has been further demonstrated using PtdSer-expressing liposomes [47, 57]and is sustained by the following observations:i) PtdSer-dependent ingestion of apoptotic cells induces TGF- $\beta$  secretion and resolution of lung inflammation [57];ii) inhibition of PtdSer recognition through Annexin-V enhances the immunogenicity of irradiated tumor cells *in vivo*[58];iii) masking of PtdSer inhibits apoptotic cell engulfment and induces autoantibody production in mice [59].

Based on data from our group [52] and Peter Henson's group [57],some authors have speculated that apoptotic leukocytes present in blood products may be responsible for transfusion-related immunosuppression[38, 60]. Thus, the first consequences of PtdSer-expressing apoptotic cells in blood products may be a transient immunosuppression [38, 60]—responsible for an increase in infection rate and of cancer relapse [8]—,or tolerance induction —as observed after DST[9-11]—when Treg have been generated.However, as discussed below (see Paragraph 4), apoptotic leukocytes become secondarily necrotic in the absence of phagocytes[45, 46]. This may certainly occur in blood productbags. Necrotic cells, through the release of damage-associated molecular patterns (DAMP) [61], may become immunogenic [42, 61]. The same process may occur for platelets [62]. Necrotic



platelets may represent the procoagulant form of platelets [62]. Thus, hemostatic activation of platelets or their byproducts may link thrombosis and inflammation to amplify lung microvascular damage during non immune TRALI [5].

### **3.2. Immune functions of microparticles and potential consequences in transfusion**

Cell surface PtdSer expression is a common feature of microparticles whatever their cell origin [40, 45, 47]. Phosphatidylserine exposure at cell surface is involved in the procoagulant activity of circulating microparticles [41]: including PMP [63], but also RMP [64]. However, their function on innate immune response is less clear. We and others have addressed the effect of PtdSer-microparticles on APC [65-72]. Incubation of neutrophil-derived microparticles (NMP) inhibits secretion of inflammatory cytokines (IL-8, TNF) by macrophages in response to TLR4 ligand, LPS and TLR2 ligand, zymosan [65]. The same effect is observed using macrophages [68, 70-72] or other APC (i.e., cDC [67, 69, 71, 72], monocytes [66] or B cells [66]) incubated with other microparticles derived from different circulating cells: platelets [69, 72], neutrophils [65, 67, 71], RBC [68], T cells [69], endothelial cells [69] as well as tumors cells [66, 70]. Thus, PtdSer-expressing microparticles exert an anti-inflammatory response through PtdSer expression [65, 70] and TGF- $\beta$  secretion [65, 70-72]. Moreover, the Mer receptor tyrosine kinase implicated in the binding of PtdSer ligands (GAS-6 or protein S) is required for alteration of APC functions by NMP [71]. Thus, PtdSer-expressing microparticles participate in transfusion-related immunosuppression as apoptotic cells do. However, data report the increase of microparticle number in stored blood products (Table 1) and the impact of blood product storage on TRALI occurrence [5]. In line with these observations, we reported recently that endothelial-derived microparticles (EMP) (found in FFP and representing around 0.5% of microparticles [33]) induce the activation of a particular subset of dendritic cells, PDC [69]. PDC play a major role in immune responses against viruses by the secretion of interferon-alpha and are implicated in autoimmune diseases, such as psoriasis or lupus [73]. Incubation of EMP induces the increase of costimulatory molecules on PDC and therefore polarization of naive CD4<sup>+</sup> T

cells into pro-inflammatory Th1 T cells by EMP-stimulated PDC. Stimulation of PDC by EMP induces the production of inflammatory cytokines IL-6 and IL-8 [69]. Overall, depending on the considered APC, microparticles favor inflammation. This suggests that PtdSer-expressing microparticles present in blood products may favor and/or sustain inflammation.

#### **4. Conclusion and perspectives**

What are the next steps to answer the question on the role of PtdSer-expressing cell dusts in the modulation of immune responses after transfusion? The next steps are to characterize or identify factors involved in the triggering of inflammation or its inhibition and produced during blood product storage or process. Several factors influence the immune responses against dying cells [42]. We can speculate on some factors, including: i) the number of PtdSer-expressing cell byproducts contained per blood product, as the immunogenicity of apoptotic cells may be proportional to the number of cells [42]; ii) the occurrence of secondary necrosis [61] (see above) and so the passive release of intracellular DAMP that overpasses the inhibitory signals delivered by PtdSer. One of these DAMP can be the heme released from stored RBC which signals *via* TLR4 [74]; iii) the size of cell byproducts and especially microparticles, since these latter exert different functions according to their size [30, 75]. Moreover, APC, such as PDC, respond only to lower sized synthetic particles [76]. This may explain the different responses observed between “amateur” phagocytes (PDC) versus professional phagocytes (cDC/macrophages) after incubation with microparticles [69]. The size of cell byproducts diminishes during plasma filtration as assessed by dynamic light scattering from 101 to 464 nm in unfiltered FFP *versus* 21 to 182 nm after 0.2  $\mu$ m filtration process [36]; iv) expression of the recently described PtdSer receptors [46] on different APC subsets may also explain the different responses between PDC *versus* cDC/macrophages [69] and may impact on the overall immune response. Finally, one has to evoke that microparticles are linked with apoptotic cells and that apoptotic cells and microparticles represent a same continuum. Indeed, PMP are generated by a loss of membrane integrity [18] and PMP found in platelet concentrates are linked to platelet apoptosis rather than platelet activation

[16]. Apoptotic blebs released early during apoptotic process are due to microvesiculation of cell membrane and thus correspond to microparticles/ectosomes[47]. In contrast, late apoptotic bodies –produced at the end of the apoptotic process when apoptotic cell clearance is delayed or altered– differ from microparticles in size and composition, since plasma membrane has been substituted by membranes from internal compartments[47, 77]. The function of late apoptotic bodies is different from early stage apoptotic cells. While APC incubated with early apoptotic cells generate Treg [50, 51], cDC matured with late apoptotic blebs rather induce pro-inflammatory Th17 cells [78]. Concomitant analysis of cell dusts in blood products and collection of clinical data from transfused patients is the only way to determine the role of PtdSer-expressing cell byproduct in transfusion setting.

**Acknowledgements:** We are grateful to Sarah Odrion for her help in manuscript editing, and the members of our laboratory for their work. Our studies in the fields of this review are supported by grants from the Association pour la Recherche sur le Cancer (ARC) (#5084 to SP), the Etablissement Français du Sang (#2011-05 to SP, #2011-11 to PS), the Association Recherche et Transfusion (2010 to FGO), the APICHU CHU Besancon (“IMIB” project API 3A CHU 2011 to FGO), and the Fondation Transplantation (# to FA).

**Conflict of interest:** the authors have not declared any conflict of interest.

## References

1. Ozier Y, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. *Transfusion* 2011; 51:2102-10.
2. Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. *Blood* 2011; 117:1463-71.
3. Eder AF, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. *Transfusion* 2007; 47:599-607.
4. Sachs UJ. Recent insights into the mechanism of transfusion-related acute lung injury. *Curr Opin Hematol* 2011; 18:436-42.
5. Lee JS, Gladwin MT. Bad blood: the risks of red cell storage. *Nat Med* 2010; 16:381-2.
6. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. *Transfus Med Rev* 2010; 24:77-124.
7. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. *Transfusion* 1996; 36:175-86.
8. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. *Blood Rev* 2007; 21:327-48.
9. Opelz G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. *Transplantation* 1997; 63:964-7.
10. Flye MW, et al. Donor-specific transfusions have long-term beneficial effects for human renal allografts. *Transplantation* 1995; 60:1395-401.
11. Marti HP, et al. Effect of donor-specific transfusions on the outcome of renal allografts in the cyclosporine era. *Transpl Int* 2006; 19:19-26.
12. Rumsby MG, Trotter J, Allan D, Michell RH. Recovery of membrane micro-vesicles from human erythrocytes stored for transfusion: a mechanism for the erythrocyte discocyte-to-spherocyte shape transformation. *Biochem Soc Trans* 1977; 5:126-8.
13. Mincheff M. Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. *Vox Sang* 1998; 74 Suppl 2:189-200.
14. Frabetti F, et al. White cell apoptosis in packed red cells. *Transfusion* 1998; 38:1082-9.
15. Martelli AM, et al. Nuclear matrix protein is released from apoptotic white cells during cold (1-6 degrees C) storage of concentrated red cell units and might induce antibody response in multiply transfused patients. *Transfusion* 2000; 40:169-77.
16. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ. The mechanism of apoptosis in human platelets during storage. *Transfusion* 2000; 40:1320-9.
17. Frabetti F, et al. White cell apoptosis in platelet concentrates. *Transfusion* 2000; 40:160-8.

18. Reid TJ, Esteban G, Clear M, Gorogias M. Platelet membrane integrity during storage and activation. *Transfusion* 1999; 39:616-24.
19. Bontadini A, Tazzari PL, Manfroi S, Tassi C, Conte R. Apoptosis in leucodepleted packed red blood cells. *Vox Sang* 2002; 83:35-41.
20. Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ. Apoptotic markers are increased in platelets stored at 37 degrees C. *Transfusion* 2003; 43:857-66.
21. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. *Transfusion* 2003; 43:526-35.
22. Leytin V, Allen DJ, Mutlu A, Mykhaylov S, Lyubimov E, Freedman J. Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. *Br J Haematol* 2008; 142:494-7.
23. Lawrie AS, Harrison P, Cardigan RA, Mackie IJ. The characterization and impact of microparticles on haemostasis within fresh-frozen plasma. *Vox Sang* 2008; 95:197-204.
24. Kriebardis AG, Antonelou MH, Stamoulis KE, Economou-Petersen E, Margaritis LH, Papassideri IS. RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components. *Transfusion* 2008; 48:1943-53.
25. Rubin O, Crettaz D, Canellini G, Tissot JD, Lion N. Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools. *Vox Sang* 2008; 95:288-97.
26. Salzer U, et al. Vesicles generated during storage of red cells are rich in the lipid raft marker stomatin. *Transfusion* 2008; 48:451-62.
27. Albany AM, Harrison P, Murphy MF. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. *Transfusion* 2009; 49:108-17.
28. Antonelou MH, Kriebardis AG, Stamoulis KE, Economou-Petersen E, Margaritis LH, Papassideri IS. Red blood cell aging markers during storage in citrate-phosphate-dextrose-saline-adenine-glucose-mannitol. *Transfusion* 2010; 50:376-89.
29. Cookson P, et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. *Transfus Med* 2010; 20:392-402.
30. Jy W, Horstman LL, Ahn YS. Microparticle size and its relation to composition, functional activity, and clinical significance. *Semin Thromb Hemost* 2010; 36:876-80.
31. Sugawara A, Nollet KE, Yajima K, Saito S, Ohto H. Preventing platelet-derived microparticle formation--and possible side effects--with prestorage leukofiltration of whole blood. *Arch Pathol Lab Med* 2010; 134:771-5.
32. Xu Y, Nakane N, Maurer-Spurej E. Novel test for microparticles in platelet-rich plasma and platelet concentrates using dynamic light scattering. *Transfusion* 2011; 51:363-70.

33. Matijevic N, Wang YW, Kostousov V, Wade CE, Vijayan KV, Holcomb JB. Decline in platelet microparticles contributes to reduced hemostatic potential of stored plasma. *Thromb Res* 2011; 128:35-41.
34. Keating FK, Butenas S, Fung MK, Schneider DJ. Platelet-white blood cell (WBC) interaction, WBC apoptosis, and procoagulant activity in stored red blood cells. *Transfusion* 2011; 51:1086-95.
35. Jy W, Ricci M, Shariatmadar S, Gomez-Marin O, Horstman LH, Ahn YS. Microparticles in stored red blood cells as potential mediators of transfusion complications. *Transfusion* 2011; 51:886-93.
36. Lawrie AS, Albanan A, Cardigan RA, Mackie IJ, Harrison P. Microparticle sizing by dynamic light scattering in fresh-frozen plasma. *Vox Sang* 2009; 96:206-12.
37. Jacobson MD, Burne JF, Raff MC. Programmed cell death and Bcl-2 protection in the absence of a nucleus. *Embo J* 1994; 13:1899-910.
38. Dzik WH. Apoptosis, TGF beta and transfusion-related immunosuppression: Biologic versus clinical effects. *Transfus Apher Sci* 2003; 29:127-9.
39. Snyder EL, Kuter DJ. Apoptosis in transfusion medicine: of death and dying--is that all there is? *Transfusion* 2000; 40:135-8.
40. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 2009; 9:581-93.
41. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. *Thromb Haemost* 2001; 85:639-46.
42. Griffith TS, Ferguson TA. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. *Immunity* 2011; 35:456-66.
43. Saas P, Bonnefoy F, Kury-Paulin S, Kleinclauss F, Perruche S. Mediators involved in the immunomodulatory effects of apoptotic cells. *Transplantation* 2007; 84:S31-4.
44. Saas P, Gaugler B, Perruche S. Intravenous apoptotic cell infusion as a cell-based therapy toward improving hematopoietic cell transplantation outcome. *Ann N Y Acad Sci* 2010; 1209:118-26.
45. Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. *J Pathol* 2011; 223:177-94.
46. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. *Immunity* 2011; 35:445-55.
47. Frey B, Gaipf US. The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. *Semin Immunopathol* 2011; 33:497-516.
48. Stuart LM, Lucas M, Simpson C, Lamb J, Savill J, Lacy-Hulbert A. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. *J Immunol* 2002; 168:1627-35.

49. Perruche S, Saas P, Chen W. Apoptotic cell-mediated suppression of streptococcal cell wall-induced arthritis is associated with alteration of macrophage function and local regulatory T-cell increase: a potential cell-based therapy? *Arthritis Res Ther* 2009; 11:R104.
50. Kleinclaus F, et al. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. *Cell Death Differ* 2006; 13:41-52.
51. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. *Nat Med* 2008; 14:528-35.
52. Bittencourt MC, et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. *Blood* 2001; 98:224-30.
53. Bonnefoy F, et al. Plasmacytoid dendritic cells play a major role in apoptotic leukocyte-induced immune modulation. *J Immunol* 2011; 186:5696-705.
54. Perruche S, Kleinclaus F, Bittencourt Mde C, Paris D, Tiberghien P, Saas P. Intravenous infusion of apoptotic cells simultaneously with allogeneic hematopoietic grafts alters anti-donor humoral immune responses. *Am J Transplant* 2004; 4:1361-5.
55. Sun E, et al. Allograft tolerance induced by donor apoptotic lymphocytes requires phagocytosis in the recipient. *Cell Death Differ* 2004; 11:1258-64.
56. Miyake Y, Asano K, Kaise H, Uemura M, Nakayama M, Tanaka M. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. *J Clin Invest* 2007; 117:2268-78.
57. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. *J Clin Invest* 2002; 109:41-50.
58. Bondanza A, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. *J Exp Med* 2004; 200:1157-65.
59. Asano K, et al. Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice. *J Exp Med* 2004; 200:459-67.
60. Dzik WH, Mincheff M, Puppo F. An alternative mechanism for the immunosuppressive effect of transfusion. *Vox Sang* 2002; 83 Suppl 1:417-9.
61. Kono H, Rock KL. How dying cells alert the immune system to danger. *Nat Rev Immunol* 2008; 8:279-89.
62. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? *Blood* 2010; 116:2011-8.
63. Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. *Thromb Haemost* 2010; 103:1044-52.

64. Tissot JD, Rubin O, Canellini G. Analysis and clinical relevance of microparticles from red blood cells. *Curr Opin Hematol* 2010; 17:571-7.
65. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. *Blood* 2004; 104:2543-8.
66. Koppler B, Cohen C, Schlondorff D, Mack M. Differential mechanisms of microparticle transfer to B cells and monocytes: anti-inflammatory properties of microparticles. *Eur J Immunol* 2006; 36:648-60.
67. Eken C, Gasser O, Zenhausern G, Oehri I, Hess C, Schifferli JA. Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells. *J Immunol* 2008; 180:817-24.
68. Sadallah S, Eken C, Schifferli JA. Erythrocyte-derived ectosomes have immunosuppressive properties. *J Leukoc Biol* 2008; 84:1316-25.
69. Angelot F, et al. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. *Haematologica* 2009; 94:1502-12.
70. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. *Cancer Lett* 2009; 283:168-75.
71. Eken C, Martin PJ, Sadallah S, Treves S, Schaller M, Schifferli JA. Ectosomes released by polymorphonuclear neutrophils induce a MerTK-dependent anti-inflammatory pathway in macrophages. *J Biol Chem* 2010; 285:39914-21.
72. Sadallah S, Eken C, Martin PJ, Schifferli JA. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. *J Immunol* 2011; 186:6543-52.
73. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. *Immunol Rev* 2010; 234:142-62.
74. Figueiredo RT, et al. Characterization of heme as activator of Toll-like receptor 4. *J Biol Chem* 2007; 282:20221-9.
75. Pelletier F, et al. Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. *J Invest Dermatol* 2011; 131:1573-6.
76. Rettig L, et al. Particle size and activation threshold: a new dimension of danger signaling. *Blood* 2010; 115:4533-41.
77. Franz S, et al. After shrinkage apoptotic cells expose internal membrane-derived epitopes on their plasma membranes. *Cell Death Differ* 2007; 14:733-42.
78. Fransen JH, et al. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. *Arthritis Rheum* 2009; 60:2304-13.



**Table 1. Phosphatidylserine-expressing cell by products in labile blood products**

Phosphatidylserine-expressing cell byproducts	Blood products in which cell byproducts have been identified	Process generating cell byproducts*	References
RMP	RBC	cold storage (day 10 to day15)	Rumsby et al., 1977[12]
Apoptotic leukocytes (neutrophils, lymphocytes)	RBC	cold storage (48 hours)	Frabetti et al., 1998[14]
Apoptotic leukocytes microparticles**	RBC	cold storage	Mincheff et al., 1998[13]
Apoptotic leukocytes	platelets	cold storage (+4°C)	Reid et al., 1999[18]
Apoptotic leukocytes	Platelets	storage and $\gamma$ -irradiation (20 Gy)	Frabetti et al., 2000[17]
Apoptotic platelets	Platelets	storage	Li et al., 2000[16]
Apoptotic leukocytes	RBC	cold storage	Martelli et al., 2000[15]
Apoptotic leukocytes	RBC	filtration (around 50% at day 0), storage (day 10 $\approx$ 40% in non leukoreduced vs. $\approx$ 90%)	Bontadini et al., 2002[19]
Apoptotic platelets	Platelets	storage (37°C is also tested, 3 hours)	Bertino et al., 2003[20]
Apoptotic platelets	Platelets	storage	Perrotta et al., 2003[21]
RMP	RBC	cold storage	Kriebardis et al., 2008[24]
PMP and RMP	Plasma	filtration (0.2 $\mu$ m, RMP decrease but not PMP decrease)	Lawrie et al., 2008[23]
Apoptotic platelets	Platelets	storage	Leytin et al., 2008[22]
RMP	RBC	cold storage (4°C, a 20-fold increase)	Rubin et al., 2008[25]
RMP	RBC	cold storage	Salzer et al., 2008[26]
Apoptotic platelets	Platelets	storage	Albanyan et al., 2009[27]
RMP	RBC	cold storage, modulation by conservation solution	Antonelou et al., 2010[28]
Apoptotic platelets	Platelets	storage	Cookson et al., 2010[29]
RMP	RBC	storage	Jy et al., 2010[30]
microparticles	FFP	filtration (“high sized” MP removal)	Lawrie et al., 2009[36]
PMP	RBC	filtration (PMP decrease)	Sugawara et al., 2010[31]
RMP	RBC	cold storage	Jy et al., 2011[35]
Apoptotic leukocytes (neutrophils, monocytes)	RBC	cold storage (4°C – day 10-15)	Keating et al., 2011[34]
PMP (> 85%)	FFP	storage (PMP decrease)	Matijevic et al., 2011[33]
PMP	Platelets	storage	Xu et al., 2011[32]

**Abbreviations used:**FFP, fresh frozen plasma; PMP, platelet-derived microparticles; RBC, red blood cells; RMP, red blood cell-derived microparticles; RT, room temperature. \*Conditions of storage for RBC and platelets are 42 days at 1 - 6°C (mentioned as “cold storage” in the Table unless if specified in brackets) and 5 -7 days at 20 - 24°C (unless specified in brackets), respectively. Some information was also added in brackets such as the time where cell dusts were identified or the percentage of dying/dead cells, etc. \*\* microparticles were not formally identified but platelets were labeled with a fluorescent marker and small fluorescent fragments were identified in supernatant.

## Figure legends

### **Figure 1. Potential consequences of phosphatidylserine-expressing cell byproducts in**

**transfusion.** Interactions of PtdSer-expressing cell dusts (apoptotic cells or microparticles) may lead to antigen-presenting cell (APC) activation or inhibition. APC activation may trigger inflammation and be involved in TRALI while APC inhibition may exert transient immunosuppression or tolerance.

Blood product process or storage may influence the generation of PtdSer-expressing cell dusts (see table 1).

### **Figure 2. The immunomodulatory effects of apoptotic leukocytes.**

Early during the apoptotic program, PtdSer-exposure occurs leading to apoptotic cell removal by macrophages (MΦ) or conventional dendritic cells (cDC). This uptake by APC induces the production of anti-inflammatory factors and concomitantly inhibits the synthesis of inflammatory cytokines [43]. These APC are refractory to TLR activation. This leads to a transient immunosuppressive microenvironment. If APC from this microenvironment migrate to secondary lymphoid organs, naive T cells are converted into inducible regulatory T cells. This leads to tolerance against apoptotic cell-derived

antigens. Abbreviations used: HGF, hepatocyte growth factor; IL-, interleukin; NO, nitrite oxide; PGE-2, prostaglandin-E2; TGF, transforming growth factor; TNF, tumor necrosis factor.